Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, Jiang G, Chen R, Han J, Jiang M, Qiao S, Liu J, Song M, Song L, Du Y, Chang Z, Wang M, Dong M, Zhong Y, Yu P, Zhang X, Zong H.
Jin S, et al. Among authors: li q.
Int J Cancer. 2023 Apr 15;152(8):1648-1658. doi: 10.1002/ijc.34372. Epub 2022 Dec 1.
Int J Cancer. 2023.
PMID: 36444498
Clinical Trial.